Related Experiment Video
Updated: Jul 18, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Therapy and management of systemic AL (primary) amyloidosis
Giovanni Palladini1, Vittorio Perfetti, Giampaolo Merlini
1Biotechnology Research Laboratories, Centre for Amyloidosis, Department of Biochemistry, "Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo", Pavia, Italy.
Abstract:
The optimal treatment of immunoglobulin light chain amyloidosis (AL) patients requires early diagnosis, correct amyloid typing, effective treatment and careful supportive therapy. In the last few years the therapeutic arsenal for the management of AL has been considerably enriched. Cardiac dysfunction can be accurately monitored by measuring the serum concentration of natriuretic peptide type-B and cardiac troponins and the quantitative test for circulating free light chains allows an easy assessment of haematological response to chemotherapy. These new tools can be combined in order to maximise the improvement of organ dysfunction and minimise toxicity, adapting the intervention to each patient.
Related Concept Videos
Alzheimer's Disease: Treatment
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Chronic Pancreatitis II: Collaborative Care
Assessment:
Nephrotic Syndrome II : Assessment and Medical Management
Atherosclerosis IV: Nursing Management
